Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$20.10M$20.10M+51.8% vs Q2 2023 Net Income-$2.75M-$2.75MN/M vs Q2 2023 EPS Diluted-$0.03-$0.03N/M vs Q2 2023 Operating Income$55,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,041,000N/M Margins · derivedOperating margin0.3%+32.1 pt vs Q2 2023
Net margin-13.7%+30.1 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 6, 2024 · 37 d after period end